Tezepelumab NAVIGATOR trial in severe, uncontrolled asthma patients meets primary endpoint

This article was originally published here

NAVIGATOR met the primary endpoint with tezepelumab added to standard of care (SoC) demonstrating a statistically significant and clinically meaningful1 reduction in the annualized asthma exacerbation rate (AAER) over

The post Tezepelumab NAVIGATOR trial in severe, uncontrolled asthma patients meets primary endpoint appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply